Histone Deacetylase (HDAC) Inhibition as a Novel Treatment for Diabetes Mellitus
Histone Deacetylase (HDAC) Inhibition as a Novel Treatment for Diabetes Mellitus
复制标题
DOI：
10.2119/molmed.2011.00021
复制
发表时间：
2011-05-01
影响因子：
5.7
通讯作者：
Mandrup-Poulsen, Thomas
中科院分区：
文献类型：
--
作者：
Christensen, Dan P.;Dahllof, Mattias;Mandrup-Poulsen, Thomas
这两种常见形式的糖尿病都有炎症发病机制，其中免疫和代谢因素汇聚到白介素LP上，作为胰岛素抵抗和β细胞衰竭的关键介质。除了改善胰岛素抵抗和预防β细胞炎症损伤外，有证据表明糖尿病与组蛋白脱乙酰酶(HDACs)存在遗传关联：组蛋白脱乙酰酶抑制剂(HDACi)促进β细胞的发育、增殖、分化和功能，并对晚期糖尿病微血管并发症产生积极影响。在这里，我们回顾了这一证据，并提出了进行临床前研究和临床试验的强有力的理由，目的是测试HDACi作为糖尿病新疗法的实用性。(C)2011年范斯坦医学研究所，网址：http://www.molmed.org doi：10.2119/molmed.2011.00021
Both common forms of diabetes have an inflammatory pathogenesis in which immune and metabolic factors converge on interleukin-lp as a key mediator of insulin resistance and beta-cell failure. In addition to improving insulin resistance and preventing beta-cell inflammatory damage, there is evidence of genetic association between diabetes and histone deacetylases (HDACs): and HDAC inhibitors (HDACi) promote beta-cell development, proliferation, differentiation and function and positively affect late diabetic microvascular complications. Here we review this evidence and propose that there is a strong rationale for preclinical studies and clinical trials with the aim of testing the utility of HDACi as a novel therapy for diabetes. (C) 2011 The Feinstein Institute for Medical Research, www.feinsteininstitute.org Online address: http://www.molmed.org doi: 10.2119/molmed.2011.00021